HALF-PINT试验中不同炎症表型患者对强化血糖控制反应异质性的生物学机制
该研究基于HALF-PINT试验中293例高血糖合并心/肺衰竭患儿(250例低炎症表型、43例高炎症表型)的740份血浆细胞因子和全血转录组样本,在治疗前及治疗后第0、2、4天采集。高炎症表型患儿基线炎症、细胞周期活性和免疫代谢相关基因表达更高。与目标血糖150-180 mg/dl相比,高炎症患儿接受目标血糖80-110 mg/dl的强化血糖控制后,炎症细胞因子、固有免疫基因表达和血红素代谢基因表达下降更明显,淋巴细胞基因表达升高。因果中介检验提示这些变化部分解释了高炎症亚组中强化血糖控制观察到的死亡获益。结论认为这些发现加深了对炎症表型生物学机制的理解,并为高炎症患儿强化血糖控制的死亡获益提供了生物学 insight。
要点
- 在HALF-PINT试验高炎症表型患儿中,目标血糖80-110 mg/dl较150-180 mg/dl使炎症细胞因子、固有免疫基因表达和血红素代谢基因表达下降更明显,淋巴细胞基因表达升高。
- 因果中介检验提示上述生物学变化部分解释了高炎症亚组中强化血糖控制观察到的死亡获益。
- 高炎症表型患儿基线炎症、细胞周期活性和免疫代谢相关基因表达高于低炎症表型。
- 研究纳入293例高血糖合并心/肺衰竭患儿,其中高炎症表型43例、低炎症表型250例,共分析740份血样。
- 上述机制探索基于HALF-PINT试验样本,作者结论为加深了对炎症表型生物学机制的理解,并非直接改变床旁血糖目标。
适用人群与场景
- HALF-PINT试验纳入的高血糖合并心/肺衰竭患儿,共293例,其中低炎症表型250例、高炎症表型43例。
- 血样采集于治疗前及治疗后第0、2、4天,共740份血浆细胞因子和全血转录组样本。
诊断标准与关键阈值
- 炎症表型分组:高炎症表型(n=43)与低炎症表型(n=250)。
- 血糖目标分组:强化血糖控制目标血糖范围80-110 mg/dl,对照目标血糖范围150-180 mg/dl。
处置流程与药物剂量
- 高炎症表型患儿接受目标血糖80-110 mg/dl的强化血糖控制后,炎症细胞因子、固有免疫基因表达和血红素代谢基因表达较目标血糖150-180 mg/dl者下降更明显,淋巴细胞基因表达升高。
- 因果中介检验提示这些生物学变化部分解释了高炎症亚组中强化血糖控制观察到的死亡获益。
研究设计与关键结果
- 研究类型为基于HALF-PINT试验的血浆细胞因子测量和全血转录组分析,纳入293例患儿(高炎症表型43例、低炎症表型250例),共740份样本,采集时间为治疗前及治疗后第0、2、4天。
- 高炎症表型患儿基线炎症、细胞周期活性和免疫代谢相关基因表达高于低炎症表型。
- 高炎症表型患儿中,目标血糖80-110 mg/dl组较目标血糖150-180 mg/dl组炎症细胞因子、固有免疫基因表达和血红素代谢基因表达下降更明显,淋巴细胞基因表达升高。
- 因果中介检验提示上述变化部分解释了高炎症亚组中强化血糖控制观察到的死亡获益。
证据类型、等级与局限
- 证据类型:基于随机对照试验HALF-PINT的血浆细胞因子和全血转录组分析。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为这些发现加深了对炎症表型生物学机制的理解,并为高炎症患儿强化血糖控制的死亡获益提供了生物学 insight。
- 原文未据此给出床旁血糖目标调整的推荐。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
Rationale: Tight glycemic control (TGC) with insulin has not consistently shown benefit in critically ill patients. We previously reported that the subset of children with a hyperinflammatory subphenotype benefited from TGC in the HALF-PINT (Heart and Lung Failure - Pediatric Insulin Titration) study of hyperglycemic children with heart and lung failure and the IIT-SBPP (Intensive Insulin Treatment - Severely Burned Pediatric Patients) study in severely burned pediatric patients. However, whether this effect was mediated through a reduction in inflammation or some other biologic process is not fully understood. Objectives: To deepen the understanding of inflammatory subphenotypes and explore the biologic mechanisms underlying heterogeneous response to TGC. Methods: Plasma cytokine measurements and whole-blood transcriptomics from 740 blood samples collected on Pre- and Post-treatment Study Days 0, 2, and 4 from 293 HALF-PINT participants (n = 250 hypoinflammatory and n = 43 hyperinflammatory) were used to identify cytokine and gene expression signatures of differential responses to TGC. Measurements and Results: Patients with the hyperinflammatory subphenotype had greater baseline expression of genes relating to inflammation, cell-cycle activity, and immunometabolism. Hyperinflammatory patients treated to a target glucose range of 80-110 mg/dl experienced greater reductions in inflammatory cytokines, innate immune gene expression, and heme metabolism gene expression, as well as an increase in lymphocyte gene expression, compared with those treated to a target range of 150-180 mg/dl. Causal mediation testing indicated that these changes partly explained the observed mortality benefit of TGC in the hyperinflammatory subgroup of patients. Conclusions: These findings expand our understanding of the biology underlying inflammatory subphenotypes and provide biologic insight into the mortality benefit of TGC in hyperinflammatory children.
参考来源
- Zinter MS, Taylor CS, Markovic D, et al. Biologic Mechanisms Underlying the Heterogeneous Response to Tight Glycemic Control among Differentially Inflamed Patients in the HALF-PINT Trial. Am J Respir Crit Care Med. 2025. PMID: 40493436. doi:10.1164/rccm.202409-1719OC
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。